Trial Profile
Open-label treatment with atomoxetine hydrochloride in child and adolescents with attention-deficit/hyperactivity disorder and comorbid dyslexia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2005
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 13 Nov 2005 New trial record.